Nunnally has been Voyager’s Chief Business Officer since 2019. He joined the company in 2018 as Vice President, Corporate and Business Development. His life sciences career spans two decades, focusing on genetically- and genomically-driven technologies and medicines for organizations ranging from early-stage biotechs to Fortune 500 pharma companies. Prior to joining Voyager, Nunnally served as Vice President, Corporate and Business Development, and Associate GeneralCounsel at Foundation Medicine, where he led transactions relating to its biopharmaceutical business in comprehensive genomic profiling, companion diagnostics, and data products and directed the company’s intellectual property strategy. Nunnally represented Foundation Medicine from its Series B financing through IPO and co-led the R&D collaboration component of a broad strategic transaction through which Roche acquired a majority interest in Foundation Medicine. Previously, Nunnally spent 10 years as an attorney at the law firm Wilmer, Cutler, Pickering, Hale and Dorr LLP, where he represented a wide array of leading pharmaceutical and biotechnology clients. Nunnally received a B.A. with double majors in biology and law, jurisprudence and social thought from Amherst College and a J.D. from Boston University School of Law with a concentration in intellectual property law.